DEFA14A: Aclarion Adjourns Special Stockholder Meeting to March 5th for Additional Vote Solicitation

Aclarion, Inc. has adjourned its Special Meeting of Stockholders to March 5, 2025, to solicit additional votes regarding proposals outlined in the definitive proxy statement.

Summary

• Aclarion, Inc. announced the adjournment of its Special Meeting of Stockholders, originally scheduled for February 28, 2025.
• The meeting has been moved to Wednesday, March 5, 2025, at 9:30 a.m. Mountain Time.
• The purpose of the adjournment is to solicit additional votes on the proposals detailed in the company's definitive proxy statement filed with the SEC on February 3, 2025.
• The reconvened meeting will be held at Aclarion's corporate office in Broomfield, Colorado.
• The record date for determining stockholders eligible to vote remains January 6, 2025.
• Stockholders who have already submitted their proxies do not need to take any action unless they wish to change their vote.
• Stockholders can change their vote by submitting a new proxy with a later date or voting online by 11:59 p.m. Mountain Time on March 4, 2025.
• Aclarion is a healthcare technology company focused on optimizing clinical treatments for low back and neck pain using Magnetic Resonance Spectroscopy (MRS), artificial intelligence, and a proprietary biomarker.
• Aclarion's technology addresses the $134.5B U.S. low back and neck pain market.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the announcement primarily concerns the procedural matter of adjourning a meeting. There's no explicit positive or negative financial news.

Positives

• Aclarion is actively seeking to ensure sufficient stockholder participation in the Special Meeting.
• The company's focus on leveraging technology like MRS and AI to address the large low back and neck pain market is a positive strategic direction.

Risks

• The adjournment of the Special Meeting suggests potential challenges in securing sufficient stockholder approval for the proposals.
• Forward-looking statements are subject to risks and uncertainties detailed in the company's SEC filings, including Forms 10-K and 10-Q.

Future Outlook

The company's future results are subject to risks and uncertainties, as detailed in their SEC filings.

Industry Context

Aclarion operates in the healthcare technology sector, specifically targeting the large and growing market for treatments related to low back and neck pain. The company's use of MRS and AI reflects a trend towards leveraging advanced technologies to improve diagnostics and treatment outcomes in healthcare.

Stakeholder Impact

• Shareholders are encouraged to participate in the voting process.
• The outcome of the Special Meeting could impact the company's strategic direction and future performance.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will reconvene the Special Meeting on March 5, 2025.

Key Dates

Keywords

Special Meeting, Stockholders, Adjournment, Proxy Statement, Aclarion, ACON, ACONW, MRS, Artificial Intelligence, Low Back Pain, Neck Pain